Eli Lilly and Company

Richard Paul Beckmann

Bharvin Kumar Patel

Teresa F Burke

Stephanie J Lemke

Kimberly S Cocke

Gregory Paul Donoho

Aimee Karis Lin

Volker Wacheck

Medicaments for use in treating acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, malignant melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenoid cystic carcinoma (ACC), colorectal cancer, prostate cancer, or medulloblastoma in a patient by administering simultaneously, separately, or sequentially, 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, and N-[5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof.

Combination therapy with Notch and CDK4/6 inhibitors for the treatment of cancer

The present invention describes a protein kinase which catalyzes the in phosphorylation of BRCA-1 protein. The present invention also describes the use of the BRCA-1 protein kinase as a molecular target for therapeutic intervention and/or as a therapeutic tool for diagnosing and treating breast and/or ovarian cancer.

Protein kinase which specifically phosphorylates BRCA-1

Growing community of inventors

Indianapolis, IN, United States of America

Richard Paul Beckmann